Wednesday, July 8, 2026

pharma · Acute Ischemic Stroke · Chronic Kidney Disease · DMAC

DiaMedica Therapeutics

DiaMedica Therapeutics is a pharma organization headquartered in Minneapolis, USA. It trades on NYSE under ticker DMAC. Primary therapeutic focus areas include Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type

Minneapolis, USA HQ
45 Employees
Public company Type
DMAC · NYSE Ticker
Company details
Status
Public
HQ
Minneapolis, USA
Employees
45
Programs
8
Drugs
7
Patents
9

Quick answer

DiaMedica Therapeutics is a pharma organization headquartered in Minneapolis, USA. It trades on NYSE under ticker DMAC. Primary therapeutic focus areas include Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type 2, Kidney Diseases, Pre-Eclampsia. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 9 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3), phase 3 (2), phase 1 (2).

Company snapshot

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with a focus on preeclampsia and acute ischemic stroke. For more information please visit www.diamedica.com.

  • 8 active pipeline program(s) linked via ClinicalTrials.gov.
  • 9 US patent(s) indexed to this assignee profile.
  • 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for DiaMedica Therapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for DiaMedica Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 7 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for DiaMedica Therapeutics.

  1. Clinical update

    DM199-2021-001 — Phase 3

  2. Clinical update

    Recombinant human tissue kallikrein — Phase 1

  3. Clinical update

    Recombinant human tissue kallikrein — Phase 3

  4. Clinical update

    Recombinant human tissue kallikrein — Phase 2

  5. Clinical update

    DM199 — Unknown

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is DiaMedica Therapeutics?

    DiaMedica Therapeutics is a pharma organization headquartered in Minneapolis, USA. It trades on NYSE under ticker DMAC. Primary therapeutic focus areas include Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type 2, Kidney Diseases, Pre-Eclampsia. NovaPharmaNews links 8 c

  • Is DiaMedica Therapeutics publicly traded?

    Yes. DiaMedica Therapeutics is listed with ticker DMAC on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does DiaMedica Therapeutics develop or market?

    We link 7 drug profile(s) where DiaMedica Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/diamedica-therapeutics#company-drugs.

  • What are the latest developments for DiaMedica Therapeutics?

    In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

  • What therapeutic areas does DiaMedica Therapeutics focus on?

    DiaMedica Therapeutics focuses on Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type 2 based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
16
Neurology
1